Amgen

IMLYGIC

Manufacturer:

Amgen

Imlygic HCPCS:

J9325

HCPCS Code Descriptor:

Injection, talimogene laherparepvec, per 1 million plaque forming units

Category:

J Code

Imlygic NDCs:

55513-0079-01, 55513-0078-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Injection

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Imlygic:

IMLYGIC is an Oncology drug manufactured by Amgen and administered via the Injection route of administration. The J Code: J9325 is aligned to the drug IMLYGIC.

ACCESS PRICING AND MORE BY REGISTERING

J9325 Added Date:

January 1, 2017

J9325 Effective Date:

January 1, 2017

J9325 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Imlygic billing and coding information.
Imlygic patient assistance information can be found through Amgen Assist at the URL: https://www.amgenassist.com/copay
IMLYGIC prescribing information can be found at the link below:
Information regarding IMLYGIC’s side effects can be found at MedlinePlus